TITLE: Combined Cytotoxic and Immune Therapy for Primary Adult High-Grade Glioma

AUTHORS: Yoshie Umemura, M.D., Daniel Orringer, M.D.[2], Larry Junck, M.D.[1], Jason Heth, M.D.[2], Oren Sagher, M.D.[2], Denise Leung, M.D.[1], Aaron Mammoser, M.D.[1], Shawn Hervey-Jumper, M.D.[2], Maria L. Varela[2], Andrea Comba, Ph.D.[2], Syed M. Faisal, Ph.D.[2], Daniel Zamler, B.S.[2], Viveka N. Yadav, Ph.D.[2], Patrick Dunn, B.S.[2], Molly E.J. West, M.S.[2], Wajd Al-Holou, M.D.[2], Todd Hollon, M.D.[2], Michelle M. Kim, M.D.[3], Daniel R. Wahl, M.D., Ph.D.[3], Sandra Camelo-Piragua, M.D.[4], Andrew P. Lieberman, M.D., Ph.D.[4], Sriram Venneti, M.D., Ph.D.[4], Paul McKeever, M.D., Ph.D.[4], Theodore Lawrence, M.D., Ph.D.[3], Ryo Kurokawa, M.D., Ph.D. [5], Kait Verbal, B.S.[2], Karen Sagher[2], B.S.[2] David Altshuler, M.D.[2], Lili Zhao, Ph.D.[6], Karin Muraszko, M.D.[2] , Maria G. Castro, Ph.D.[2], Pedro R. Lowenstein, M.D., Ph.D.[2]

AFFILIATIONS: [1]Depts. Of Neurology, [2]Neurosurgery, [3]Radiation Oncology, and [4]Pathology, [5]Radiology, The University of Michigan School of Medicine, and [6]Dept. of Biostatistics, The University of Michigan School of Public Health.

CORRESPONDING AUTHOR:

Pedro R. Lowenstein, M.D., Ph.D.

Address: 4570 MSRB II, Ann Arbor, MI 48109-0650

Email: pedrol@umich.edu

Phone: 734-764-0851

Abstract

BACKGROUND: High-grade gliomas are fatal with universally poor prognosis. Initiation of effective cancer immune responses requires functional immune cells, especially afferent antigen presenting cells, which are absent from the brain parenchyma.[1,2] To address this requirement, two adenoviral vectors expressing HSV1-TK and Flt3L were combined to target human gliomas. This first in human trial assessed safety, cytotoxicity, and immune recruitment to the tumor.

METHODS: Eighteen treatment-naïve adults with high-grade glioma received injections of HSV1-TK- and Flt3L-expressing adenoviral vectors to the tumor bed after maximal safe resection, at six escalating doses (total 1.1×10^{10}-2×10^{11} vp), followed by two 14-day courses of valacyclovir, and standard upfront chemoradiation. Key inclusion criteria were: age 18-75, KPS ≥70, and treatment-naïve high-grade glioma amenable to gross total resection. Patients were consented pre-operatively. Enrollment occurred intraoperatively, upon pathology confirmation.

RESULTS: The treatment was well tolerated without dose-limiting toxicity in patients with glioblastoma (n=17) (3 of the gliosarcoma variant), or anaplastic ependymoma (n=1). The maximal-tolerated dose was not reached. The median overall-survival was 21.3 months (95%CI: 11.1, 26.1). Tissues from subsequent resections from 8 subjects showed elevated markers for CD3+ and CD8+ T cells indicating potential successful anti-glioma immunity recruitment. Multiplex immunohistochemistry on two patients indicated a change in the intratumoral redistribution of CD8+ T cells and microglia/macrophages.

CONCLUSIONS: Use of two adenoviral vectors expressing HSV1-TK and Flt3L is safe and well tolerated in newly diagnosed high-grade glioma patients. Promising multiplex immunocytochemical evidence of immune infiltration warrants further efficacy studies, possibly in combination with blockade of the inhibitory tumor microenvironment.

40 (Funded in part by Phase One Foundation, Los Angeles, CA, The Board of Governors at Cedars-Sinai
41 Medical Center, and The Rogel Cancer Center at The University of Michigan; clinicaltrials.gov:
42 NCT01811992)

43 **Background**

44 High-grade gliomas (HGG), of astrocytic, oligodendroglial or ependymal variants, are the most common
45 types of primary brain tumor in adults.[3] HGGs are associated with poor prognosis, in spite of standard
46 therapy, leading to a median overall survival (OS) around 14-16 months despite aggressive treatment
47 with surgical resection and chemoradiation.[4] Gene therapy for malignant gliomas using viral vectors
48 encoding a direct or conditional tumoricidal approach has been shown to be safe in humans, though it
49 has not demonstrated clinically significant benefits to date in large scale clinical trials.[5,6] Important
50 challenges of gene therapy remain the low efficacy of direct tumor cell killing *in situ* and limited tumor
51 and brain distribution of the transgenic therapeutic products preventing elimination of infiltrating
52 malignant cells located at various distances from the primary tumor site.[7-12]
53 Initiation of an effective immune response against cancer requires functional dendritic cells, which are
54 absent from the non-inflamed central nervous system (CNS),[13] possibly underlying the lack of anti-HGG
55 immune responses (Figure 1A). Treatment with Flt3L at the tumor bed, a cytokine known to cause
56 proliferation and differentiation of dendritic cells, recruits dendritic cells into the tumor
57 microenvironment.[14-16] Herpes simplex virus-thymidine kinase (HSV1-TK) is an enzyme that
58 phosphorylates the antiviral prodrug valacyclovir and converts it into a nucleotide analog which causes
59 cell death of mitotically active cells such as HGG.[11,17-19] By combining Flt3L and conditionally cytotoxic
60 HSV1-TK, the infiltrating dendritic cells recruited into the tumor microenvironment become exposed to
61 endogenous glioma antigens (released by HSV1-TK dependent tumor cell cytotoxicity), and become
62 activated by TLR2 agonists, such as HMGB1; these dendritic cells then become capable of inducing
63 specific anti-glioma immune responses against residual malignant glioma cells that remain post-surgical
64 excision (Figure 1B).[2,20-23] In pre-clinical studies, this approach induced both T cell immune cytotoxicity,
65 memory, and high therapeutic efficacy and eliminated a large percentage (i.e., 50-75%) of tumors in

66 various mouse models of glioblastoma.[16,24-28] The safety of this dual vector treatment in humans has not
67 been established previously, though its safety in rats, canines and marmosets has been tested earlier by
68 us.[23,29-31] We hypothesize that the co-administration of Ad-hCMV-TK and Ad-hCMV-Flt3L viral vectors to
69 the post-resection tumor bed followed by oral valacyclovir can be safely combined with standard of care
70 chemoradiation in patients with newly diagnosed high grade gliomas, and will potentially stimulate an
71 anti-HGG immune response.
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88

89 ## Methods

90 **OBJECTIVES**

91 Our primary objective was to identify the maximum tolerated dose (MTD) of Ad-hCMV-Flt3L and Ad-
92 hCMV-TK, administered into the tumor bed after maximal safe resection of malignant gliomas. The
93 secondary objective was to assess the potential benefit of Ad-hCMV- TK and Ad-hCMV-Flt3L dual-vector
94 treatment of primary malignant glioma in overall survival (OS) at 12- and 24-months from intra-operative
95 diagnosis. Exploratory objectives included the study of histological indices of inflammatory responses in
96 tumor tissue from subsequent resections, when available, as well as measures of potential surrogate
97 markers of intracranial immune responses. Viral vectors were produced at the Center for Cell and Gene
98 Therapy, Baylor College of Medicine, Houston, TX. Examples of the last yearly quality control including
99 the bioactivity of each vector is given in Figs. S1 (Ad-hCMV-TK) and S2 (Ad-hCMV-Flt3L).

100 **PATIENT POPULATION**

101 Adult patients with presumed newly diagnosed HGG who underwent maximal safe resection at the
102 University of Michigan were potentially eligible**.** Key inclusion criteria were ages 18-75, KPS ≥70, and
103 suspected newly diagnosed HGG amenable to gross total resection. Out of 21 subjects consented, two
104 failed to meet eligibility criteria. One subject was unevaluable due to early withdrawal, not due to study-
105 related toxicity, and was replaced. Eighteen subjects in all were evaluable and received study treatment.
106 Detailed inclusion and exclusion criteria are available in the Supplemental Methods Section in the
107 Supplementary Appendix.

108 Eligible subjects who provided informed consent underwent maximal safe resection as indicated in the
109 study schema (Figure 1C). Once the intra-operative pathology consultation confirmed HGG, subjects
110 were enrolled in a phase 1, open label, dose escalation safety study of Ad-hCMV-TK and Ad-hCMV-Flt3L,

111 assigned to six escalating doses in a 3+3 design (Supplemental Appendix Table S1, and Fig. S3). The
112 starting dose was Ad-hCMV-TK $1x10^{10}$ vp and Ad-hCMV-Flt3L $1x10^{9}$ vp (Cohort A), and the doses were
113 escalated respectively to $1x10^{11}$ vp and $1x10^{9}$ vp (Cohort B), $1x10^{10}$ vp and $1x10^{10}$ vp (Cohort C), $1x10^{11}$
114 vp and $1x10^{10}$ vp (Cohort D), $1x10^{10}$ vp and $1x10^{11}$ vp (Cohort E), and finally, $1x10^{11}$ vp and $1x10^{11}$ vp
115 (Cohort F).

116 The dual vectors were administered in a total volume of 2 ml to the tumor bed, divided into 0.1 ml
117 injections at 20 sites. This was followed by two 14-day cycles of oral valacyclovir 2g TID and standard-of-
118 care, upfront radiation and concurrent temozolomide per treating physician(s)**.** Valacyclovir courses
119 started at 1-3 days and 10-12 weeks after vector administration. This approach is based on our animal
120 data showing viral transgene expression up to 6 and 12 months post-delivery of adenovirus into the
121 brain.[32,33] Dose modification for valacyclovir was allowed if it was deemed necessary by the investigator
122 with approval by the medical monitor (Dose modification guidelines are detailed in the Supplemental
123 Methods Section in the Supplementary Appendix, and Table S2, Table S3).

124 This clinical trial was reviewed and approved by the Institutional Review Board-MED and registered at
125 ClinicalTrials.gov (NCT01811992). An IND was obtained from the FDA prior to the study initiation (BB-
126 IND 14574). Additional detail in study design such as surgical, medical, and radiation protocols can be
127 found in the Supplemental Methods Section in the Supplementary Appendix.

128 **STATISTICAL ANALYSIS**

129 Demographic data was summarized in a tabular format. Kaplan-Meier method was used to estimate
130 median, 12- and 24-months overall survival along with 95% confidence intervals. Overall survival was
131 defined from the time of study enrollment (the date of dual vector injection) to the time of death.

132 Progression-free survival was defined from the time of study enrollment to the time of first progression
133 or death using iRANO criteria. RStudio Version 1.3.1073 was used for statistical analysis.

134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151

152 ## Results

153 **PATIENT CHARACTERISTICS**

154 Eighteen patients with median age of 64 years (range 45-73) were assigned to six dose levels. As
155 summarized in Table 1A, eight subjects were women (44%). The KPS at the time of enrollment was 90-
156 100 in fifteen subjects (83%), 70-80 in three subjects (17%). In eleven participants (61%) radiographic
157 gross total resection was achieved prior to the dual vector administration. All participants met the
158 inclusion criteria of having the intraoperative pathology diagnosis of high-grade glioma. Final diagnosis
159 was as follows: 17 tumors (95%) were diagnosed as glioblastoma, WHO grade 4 (3 of them were of the
160 gliosarcoma subtype), and one was an "anaplastic" astrocytoma, WHO grade 3 glioblastoma (5%). All
161 tumors were IDH wildtype, and 39% (n=7) had MGMT promoter methylation.

162 **UPFRONT TREATMENT (see Supplementary Methods: Protocol Treatment Plan)**

163 Study subjects received upfront radiation and concurrent temozolomide per standard of care by treating
164 oncologists. Detail of adjuvant treatment rendered was available for 17 subjects. Details of standard of
165 care chemoradiation for one subject who elected to receive care closer to home were unavailable. The
166 one patient with "anaplastic ependymoma" received a total 59.4 Gy of radiotherapy without concurrent
167 temozolomide followed by imaging surveillance without adjuvant chemotherapy.
168 Of 16 patients with glioblastoma with known radiation details, all received concurrent temozolomide,
169 14 patients received the standard total 60 Gy, one patient received hypofractionated 40.5 Gy total, and
170 one patient received 10 Gy before interruption due to wound issues and later completed 40.5 Gy
171 between adjuvant temozolomide cycles. All 16 patients received standard-of-care sequential adjuvant
172 cyclic temozolomide (range 1-11 cycles total). One patient received bevacizumab shortly after
173 completion of concurrent chemoradiation for disease burden from post-radiation treatment changes

174 along with cyclic temozolomide. None of the subjects opted to use tumor treating fields as part of the
175 upfront treatment.

176 **SURGICAL PATHOLOGY AT SUSPECTED RECURRENCE**

177 The timing of subsequent surgeries in relation to radiographic progression is illustrated in Figure 2B.
178 Eight patients (44%) underwent at least one subsequent resection. After the dual vector and valacyclovir
179 therapy and upfront standard of care therapy, seven patients had re-operation at the time of
180 radiographically suspected tumor progression; six subjects had surgically confirmed progression though
181 the resected tissues from three of these subjects had extensive treatment related inflammation and
182 necrosis, and only <50% was tumor; one subject (ID 7) had surgically confirmed pseudoprogression.
183 Pseudoprogression was defined as ≤ 5% proliferating tumor involvement of resected tissue. One other
184 subject (ID 5) received second line therapy without surgical confirmation of first progression but
185 underwent re-resection after the second line therapy, at which time pseudoprogression was noted.

186 When further progressions were suspected, four subjects (ID 1, 2, 8, 21) underwent additional
187 resections; three had two re-resections (ID 1, 8, 21), and one subject had three re-resections (ID 2).
188 Subject ID 1, 8, and 21 had surgical confirmation of progression after first-line therapy but only <50%
189 tumor involvement of the resected tissue; subject ID 1 and 21 had similar findings at subsequent re-
190 resection with majority of the resected tissue showing treatment related changes albeit confirmed
191 progression (tumor >5%); subject ID 8 had surgically confirmed pseudoprogression after the second-line
192 therapy of procarbazine and lomustine.

193 Subject ID 2 had the diagnosis of anaplastic ependymoma from the tissue obtained from the initial
194 surgery prior to the dual vector injections, and the first surgically confirmed local recurrence showed
195 recurrent/residual anaplastic ependymoma. Subsequently, this patient developed a contralateral distant
196 lesion which was biopsied and showed high grade glioma that was morphologically different from the

197 original anaplastic ependymoma. This lesion was then resected two months later, which was notably
198 more infiltrative than the original tumor at the initial diagnosis, with features of astrocytoma with areas
199 of necrosis and microvascular proliferation consistent with glioblastoma. It was unclear if this distant
200 lesion was a new primary tumor or a dedifferentiation of the known anaplastic ependymoma.

201 **PROGRESSION-FREE AND OVERALL SURVIVAL**

202 The median overall survival (OS) from the time of enrollment was 21.3 months (95%CI: 11.1, 26.1). The
203 12-month OS was 72% (95%CI: 45.6, 0.87) and the 24-month OS was 39% (95%CI: 17.5, 60.0). (Figure
204 2A). The median progression free survival was 9.9 months (95%CI: 7.3, 13.3).
205 Pre-operative DWI (n=9) and DSC (n=18) parameters were evaluated. There were weak positive
206 correlations between baseline pre-operative nrCBV and OS, and between pre-operative nADC mean and
207 OS (r = 0.53 and 0.49, respectively). No significant correlations were found between MRI parameters and
208 survival (OS or PFS).

209 **IMMUNOCYTOCHEMISTRY ANALYSES**

210 Immunohistochemical analysis of immune infiltrating cells was performed on tumor sections at primary
211 resection, i.e., pre vector TK-Flt3L treatment, and compared with the same patient's samples taken at
212 secondary surgery due to potential tumor recurrence (n=8). There were no differences in: hematopoietic
213 CD45 positive cells (Fig. S4), monocytic lineage cells (CD68 positive cells) (Fig. S5), or dendritic cells
214 (CD11c positive cells) (Fig. S7).
215 Importantly, CD3e positive cells (T-lymphocytes) were significantly increased in the re-resection sample
216 (surgery 2), in comparison with primary resection (surgery 1) ($p<0.0001$, Fig. 3B-D). Deeper
217 characterization of T-cells showed that there was no difference in CD4+ cells (Fig. S6), while there was a
218 statistically significant increment of CD8+ cells ($p<0.0001$, Fig. 3E-G) in surgery 2 samples. Multiplex

219 immunohistochemistry on two patients confirmed the increase in CD8+ T cells, and showed that, at
220 recurrence CD8+ T cells increased their association with microglia/macrophages, illustrating the
221 anatomical basis of the potential monocyte-mediated inhibition of CD8+ T cell function.

222 **EXPLORATORY ANALYSES**

223 The neutralizing anti-adenovirus antibody titers were tested in cohorts B through F (n=15) and the results
224 summarized in Supplementary Material Table S6. The baseline anti-adenovirus antibody titers prior to
225 dual viral vector injection were between <2 to >4096. Specifically, six patients had no circulating anti-
226 adenovirus neutralizing antibodies (titer ≤ 2) at basal levels before delivery of vectors; four patients had
227 titers between 8-64; and five patients had high basal levels (512-4096).

228 Of patients that could be evaluated serially, 11 increased their antibody titer post-delivery of viral vector,
229 while two decreased their titer (by half). Increases in titer varied from large changes, i.e., from < 2 (pre)
230 to > 4096 (post), to very small increases i.e., from <2 (pre) to 16 (post).

231 Overall, in those patients whose titers increased, 3 patients doubled their titers, 2 increased titers 3
232 times, one by 4 times, one by 6 times, one by 7 times, 2 by 9 times, and one by 13 times. We did not
233 find any correlation between antibody titers and PFS or OS.

234

235

236

237

238

239

240

241 **Discussion**

242 We report on the first-in-human phase 1 clinical trial of dual cytotoxic and immune-stimulatory
243 adenoviral vector administration combined with standard-of-care consisting of maximally safe resection
244 followed by chemoradiation and adjuvant chemotherapy. The treatment was well tolerated, with no
245 dose limiting toxicity attributable to the administration of adenoviral vectors. There were occasional mild
246 to moderate toxicities, however, that were possibly related to valacyclovir, therefore reduced dose of
247 valacyclovir in future studies may be a consideration. An early study of adenovirus injected into the
248 tumor cavity post-surgical excision found toxicity at $2x10^{12}$ pfu injected.[12] Since this study, trials using
249 adenoviral vectors, including ours, have remained one log below this dose, and consequently MTDs were
250 not reached.

251 Tissue obtained at the second surgery- at potential recurrence- revealed an increase in T cells, specifically
252 CD8+ T cells. This would be an encouraging signal as it could indicate the presence of an increased
253 immune response. However, spatially resolved multiplex immunocytochemistry, indicates an increase in
254 the association of macrophages/microglia with T cells at the second surgery. This might indicate a
255 potential increased downregulation of T cell activity by macrophages/microglia, as recently
256 described.[34,35]

257 Although this study was not powered for survival analysis, the median overall survival of 21.3 months
258 (95%CI: 11.1, 26.1) is promising, especially considering that glioblastoma has a known overall historical
259 survival rate of 16-18 months, with high complexity centers reporting survivals of 19-21 months.[36] Future
260 directions may consider the inclusion of immune checkpoint blockage[37] and/or methods to reduce the
261 strong immunosuppressive glioma microenvironment.

262 Since the modern dawn of gene therapy in the 70's there have been close to sixty viral gene therapy
263 trials for brain tumors have been done using adenoviral vectors (~20 trials), HSV1 vectors (~12 trials),

264 retroviral vectors (~6 trials), and measles virus, Newcastle Disease virus, vaccinia, reovirus, Parvovirus-
265 H1, and Poliovirus-derived vectors.[10] Viral vectors have been used to deliver conditional cytotoxicity,
266 oncolysis, cytokines, and the use of checkpoint inhibitors in combination with various viral vectors.[10]
267 In gene therapy trials, clinical outcomes have been less impressive than expected, with only small
268 numbers of patients displaying longer term survival. A recent publication utilizing up to six injections of
269 intratumoral oncolytic HSV-G47Δ injections for the treatment of residual or recurrent glioblastoma in a
270 phase 2 trial reported promising one year survival rates.[38]
271 The outcome of correlative studies have been more encouraging. Various studies detected increases in
272 the number of immune cells in brain/tumor areas that had earlier been treated with gene therapy
273 vectors, potentially converting "cold" tumors into "hot" tumors.[39,40]
274 Of 13 patients who could be evaluated for serum anti-adenovirus antibody levels, 11 had an increase in
275 titer, while in 2 patients titers decreased. Titers increased from two times to thirteen times. This
276 indicates that following peri-tumoral injection of adenoviral vectors it is possible for the humoral
277 immune response to increase. There was no correlation between vector dose, serum antibody levels,
278 overall survival, or intracranial quantitative immune responses measured by immunohistochemistry.
279 In our trial we provided extended administration of the HSV1-TK substrate, valacyclovir, to two cycles.
280 The basis for extending the administration of valacyclovir is supported by preclinical data demonstrating
281 that in rodents, adenoviral vector mediated transgene expression can last up to one year.[32,33] As the
282 cytotoxic effect is only realized during the administration of valacyclovir and tumor cell division, it might
283 be sensible to extend valacyclovir administration even further to increase the cytotoxic potential of the
284 HSV1/valacyclovir combination. It could be equally important to consider multiple vector
285 administrations, as recently described.[38]

286 We had the opportunity to analyze samples from the brain tumors of eight patients that had at least two
287 brain surgeries: seven repeat surgeries were done at the time of first radiographic progression, and one
288 at second radiographic progression after having received a second-line treatment. We were able to
289 detect a statistically significant increase in CD3+ and CD8+ T cells, without changes in the other markers
290 studied. Whether the increase in T cells in the brains of the patients has a therapeutic role remains to
291 be elucidated. Future studies will need to determine the antigen specificity of tumor infiltrating T cells,
292 and whether the influx of T cells contributes to remodeling the brain tumor immune microenvironment.
293 In our studies we could not detect an increase in CD11c+ putative dendritic cells at the time of second
294 surgery. In experimental studies CD11c+ cells increase at short times post-administration of Ad-FLT3L,
295 while T cells enter the target tissue at later stages and remain there for longer. As the human samples
296 are obtained months post-vector administration, this precludes the detection of a transitory peri-
297 tumoral increase in dendritic cells. Nevertheless, we believe that the increase in the density of CD3+ and
298 CD8+ T cells is an indication that the adaptive immune response has been activated.
299 The presence of substantial numbers of T cells in the brain suggests that the addition of further immune-
300 stimulatory therapies, such as checkpoint inhibitors. Interestingly, in two patients we analyzed the brain
301 tumor tissue at both surgeries by multiplex immunohistochemistry. While this technique confirmed an
302 increase in T cells, we observed a reduction in activation markers in T cells in material from the second
303 surgery. In addition, we identified an increase in potential interactions between microglia/macrophages
304 and T cells, suggesting that while the number of T cells may be increased, their activation status may be
305 inhibited by microglia/macrophages in the tumor microenvironment. These data suggest that in addition
306 to measuring the amount of infiltrating T cells, it will be crucial that future studies determine T-cell
307 activation status, and cellular interactions within the tumor microenvironment.

308

309 **References**

310 1. Lowenstein PR. Immunology of viral-vector-mediated gene transfer into the brain: an
311 evolutionary and developmental perspective. Trends Immunol 2002;23(1):23-30. DOI:
312 10.1016/s1471-4906(01)02063-4.
313 2. Curtin JF, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain
314 tumor regression. PLoS Med 2009;6(1):e10. DOI: 10.1371/journal.pmed.1000010.
315 3. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central
316 Nervous System: a summary. Neuro Oncol 2021;23(8):1231-1251. DOI:
317 10.1093/neuonc/noab106.
318 4. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma
319 treated with radiation and temozolomide in research studies in the United States. Clin Cancer
320 Res 2010;16(8):2443-9. DOI: 10.1158/1078-0432.CCR-09-3106.
321 5. Maatta AM, Samaranayake H, Pikkarainen J, Wirth T, Yla-Herttuala S. Adenovirus mediated
322 herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant
323 glioma. Curr Gene Ther 2009;9(5):356-67. DOI: 10.2174/156652309789753365.
324 6. Castro MG, Candolfi M, Wilson TJ, et al. Adenoviral vector-mediated gene therapy for gliomas:
325 coming of age. Expert Opin Biol Ther 2014;14(9):1241-57. DOI:
326 10.1517/14712598.2014.915307.
327 7. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol
328 Ther 2005;12(4):585-98. DOI: 10.1016/j.ymthe.2005.07.357.
329 8. Longo DL, Baden LR. Exploiting Viruses to Treat Diseases. N Engl J Med 2018;379(2):194-196.
330 DOI: 10.1056/NEJMe1807181.
331 9. Brown NF, Carter TJ, Ottaviani D, Mulholland P. Harnessing the immune system in glioblastoma.
332 Br J Cancer 2018;119(10):1171-1181. DOI: 10.1038/s41416-018-0258-8.
333 10. Banerjee K, Nunez FJ, Haase S, et al. Current Approaches for Glioma Gene Therapy and
334 Virotherapy. Front Mol Neurosci 2021;14:621831. DOI: 10.3389/fnmol.2021.621831.
335 11. Wheeler LA, Manzanera AG, Bell SD, et al. Phase II multicenter study of gene-mediated
336 cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant
337 glioma. Neuro Oncol 2016;18(8):1137-45. DOI: 10.1093/neuonc/now002.
338 12. Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk
339 gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther
340 2000;1(2):195-203. DOI: 10.1006/mthe.2000.0030.
341 13. D'Agostino PM, Gottfried-Blackmore A, Anandasabapathy N, Bulloch K. Brain dendritic cells:
342 biology and pathology. Acta Neuropathol 2012;124(5):599-614. DOI: 10.1007/s00401-012-
343 1018-0.
344 14. Ali S, Curtin JF, Zirger JM, et al. Inflammatory and anti-glioma effects of an adenovirus
345 expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L
346 inhibits intracranial glioma progression. Mol Ther 2004;10(6):1071-84. (In eng). DOI:
347 10.1016/j.ymthe.2004.08.025.
348 15. Candolfi M, King GD, Yagiz K, et al. Plasmacytoid dendritic cells in the tumor microenvironment:
349 immune targets for glioma therapeutics. 2012;14(8):757.
350 16. Mineharu Y, King GD, Muhammad AK, et al. Engineering the brain tumor microenvironment
351 enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin
352 Cancer Res 2011;17(14):4705-18. DOI: 10.1158/1078-0432.CCR-11-0915.

353 17. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral
354 implantation of retroviral vector-producing cells. Nat Med 1997;3(12):1354-61. DOI:
355 10.1038/nm1297-1354.
356 18. Sasaki M, Plate KH. Gene therapy of malignant glioma: recent advances in experimental and
357 clinical studies. Ann Oncol 1998;9(11):1155-66. DOI: 10.1023/a:1008488709359.
358 19. Castro MG, Lowenstein PR. Neuro-oncology: The long and winding road--gene therapy for
359 glioma. Nat Rev Neurol 2013;9(11):609-10. DOI: 10.1038/nrneurol.2013.198.
360 20. Ali S, King GD, Curtin JF, et al. Combined immunostimulation and conditional cytotoxic gene
361 therapy provide long-term survival in a large glioma model. Cancer research 2005;65(16):7194-
362 204. (In eng). DOI: 10.1158/0008-5472.Can-04-3434.
363 21. Candolfi M, Yagiz K, Foulad D, et al. Release of HMGB1 in response to proapoptotic glioma
364 killing strategies: efficacy and neurotoxicity. Clin Cancer Res 2009;15(13):4401-14. DOI:
365 10.1158/1078-0432.CCR-09-0155.
366 22. King GD, Kroeger KM, Bresee CJ, et al. Flt3L in combination with HSV1-TK-mediated gene
367 therapy reverses brain tumor-induced behavioral deficits. Mol Ther 2008;16(4):682-90. DOI:
368 10.1038/mt.2008.18.
369 23. King GD, Muhammad AK, Curtin JF, et al. Flt3L and TK gene therapy eradicate multifocal glioma
370 in a syngeneic glioblastoma model. Neuro Oncol 2008;10(1):19-31. DOI: 10.1215/15228517-
371 2007-045.
372 24. Ghulam Muhammad AK, Candolfi M, King GD, et al. Antiglioma immunological memory in
373 response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular
374 immunity lead to tumor regression. Clin Cancer Res 2009;15(19):6113-27. DOI: 10.1158/1078-
375 0432.CCR-09-1087.
376 25. King GD, Muhammad AG, Larocque D, et al. Combined Flt3L/TK gene therapy induces
377 immunological surveillance which mediates an immune response against a surrogate brain
378 tumor neoantigen. 2011;19(10):1793-1801.
379 26. Muhammad AK, Puntel M, Candolfi M, et al. Study of the efficacy, biodistribution, and safety
380 profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for
381 glioblastoma. Clinical pharmacology and therapeutics 2010;88(2):204-13. (In eng). DOI:
382 10.1038/clpt.2009.260.
383 27. Muhammad AK, Xiong W, Puntel M, et al. Safety profile of gutless adenovirus vectors delivered
384 into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. Human gene
385 therapy methods 2012;23(4):271-84. (In eng). DOI: 10.1089/hgtb.2012.060.
386 28. Alghamri MS, McClellan BL, Avvari RP, et al. G-CSF secreted by mutant IDH1 glioma stem cells
387 abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Sci
388 Adv 2021;7(40):eabh3243. DOI: 10.1126/sciadv.abh3243.
389 29. VanderVeen N, Paran C, Appelhans A, et al. Marmosets as a preclinical model for testing “off-
390 label” use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.
391 2014;1:10.
392 30. Xiong W, Candolfi M, Liu C, et al. Human Flt3L generates dendritic cells from canine peripheral
393 blood precursors: implications for a dog glioma clinical trial. 2010;5(6).
394 31. Candolfi M, Pluhar GE, Kroeger K, et al. Optimization of adenoviral vector-mediated transgene
395 expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol
396 2007;9(3):245-58. DOI: 10.1215/15228517-2007-012.
397 32. Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes
398 simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by

399 adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 1999;5(11):1256-63.
400 DOI: 10.1038/15207.
401 33. Zermansky AJ, Bolognani F, Stone D, et al. Towards global and long-term neurological gene
402 therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1
403 thymidine kinase throughout the CNS. Mol Ther 2001;4(5):490-8. DOI:
404 10.1006/mthe.2001.0479.
405 34. Hara T, Chanoch-Myers R, Mathewson ND, et al. Interactions between cancer cells and immune
406 cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 2021;39(6):779-
407 792 e11. DOI: 10.1016/j.ccell.2021.05.002.
408 35. Chanoch-Myers R, Wider A, Suva ML, Tirosh I. Elucidating the diversity of malignant
409 mesenchymal states in glioblastoma by integrative analysis. Genome Med 2022;14(1):106. DOI:
410 10.1186/s13073-022-01109-8.
411 36. Pace A, Tanzilli A, Benincasa D. Prognostication in brain tumors. Handb Clin Neurol
412 2022;190:149-161. DOI: 10.1016/B978-0-323-85029-2.00001-4.
413 37. Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes
414 a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
415 Nat Med 2019;25(3):477-486. DOI: 10.1038/s41591-018-0337-7.
416 38. Todo T, Ito H, Ino Y, et al. Intratumoral oncolytic herpes virus G47 for residual or recurrent
417 glioblastoma: a phase 2 trial. Nat Med 2022;28(8):1630-1639. DOI: 10.1038/s41591-022-01897-
418 x.
419 39. Candolfi M, Yagiz K, Wibowo M, et al. Temozolomide does not impair gene therapy-mediated
420 antitumor immunity in syngeneic brain tumor models. Clin Cancer Res 2014;20(6):1555-1565.
421 DOI: 10.1158/1078-0432.CCR-13-2140.
422 40. Friedman GK, Johnston JM, Bag AK, et al. Oncolytic HSV-1 G207 Immunovirotherapy for
423 Pediatric High-Grade Gliomas. N Engl J Med 2021;384(17):1613-1622. DOI:
424 10.1056/NEJMoa2024947.
425

426 **TABLE 1A: Patient Demographics and Baseline Characteristics**

Characteristic	Total N=18
Median age (range)	64 (45-73)
Women – no. (%)	8 (44)
KPS – no. (%)	
90-100	15 (83)
70-80	3 (17)
Radiographic GTR – no. (%)	11 (61)
MGMT methylated – no. (%)	7 (39)
IDH mutation – no. (%)	0 (0)
Final diagnosis – no. (%)	
Glioblastoma / Gliosarcoma	17 (94)
Anaplastic ependymoma	1 (6)

427

428 **TABLE 1B: Adverse Events At Least Possibly Related to Study Treatment**

429

Event	Dual Vector Dose (N=3 per level)						Total
	A	B	C	D	E	F	N=18
	no.						*no. (%)*
Gastrointestinal disorders							
Dyspepsia, Grade 1	-	-	-	1	-	-	1 (6)
Investigations							
Creatinine increased, Grade 2	-	-	-	-	-	1	1 (6)
Nervous system disorders							
Dizziness, Grade 1	-	-	-	-	-	1	1 (6)
Encephalopathy, Grade 3	-	-	-	-	-	1*	1 (6)
Headache, Grade 1	-	-	-	1	-	-	1 (6)
Seizure, Grade 2	-	1*	-	-	-	-	1 (6)
Grade 3	1	-	-	-	-	-	1 (6)
Psychiatric disorders							
Confusion, Grade 2	-	-	-	-	-	1	1 (6)
Hallucinations. Grade 1	-	-	-	-	-	1	1 (6)
Renal and urinary disorders							
Acute kidney injury, Grade 3	-	-	-	-	-	1*	1 (6)
Skin and subcutaneous disorders							
Rash maculo-papular, Grade 1	-	1	-	-	-	-	1 (6)
Total no. patients with study related events	1	2	-	2	-	1	6 (33)

430 *Serious adverse events

Figure 1


A
Naïve glioma microenvironment
NO cytotoxity
T cells
HGG
NO tumor killing
NO release of tumor antigens & DAMPs
Lymph node
NO stimulation of adaptive anti-tumor immunity
B
Inflamed glioma microenvironment after gene therapy
HSV1-TK + Valacyclovir
HSV1-TK
Tumor killing
T cells
HGG
Release of tumor antigens & DAMPs
Lymph node
Dendritic cells
Flt3L
Antigen presentation
Dendritic cell recruitment & differentiation
Flt3L
C
Eligibility & Consent
Newly diagnosed suspected HGG
Age 18-75
KPS ≥ 70
GTR candidate
Enrollment
Frozen pathology confirmation
Dual Vector Injection
Surgery
1-3 days
Valacyclovir 2 g TID x 14 days
8-10 weeks
Valacyclovir 2 g TID x 14 days
SOC chemo-RT

Figure 2

A


Overall survival:
Median 21.3 months
12 months 72.2%
24 moonths 38.9%
All
Methylated
Unmethylated
Probability of Survival (%)
100
75
50
25
0
0
12
24
36
48
Months
Number at risk
18 17 13 11 7 4 3 2 1 0

B


Symbol Key:
* Gliosarcoma variant
** Anaplastic ependymoma
Steroid prior to study treatment
MGMT unmethylated
MGMT methylated
Suspected PD on MRI
PD surgically confirmed
< 50% tumor
PsP surgically confirmed
Subject ID
Pt02**
Pt16
Pt21
Pt08
Pt01
Pt05
Pt03
Pt07
Pt14
Pt11
Pt13
Pt18
Pt20*
Pt12*
Pt10
Pt15
Pt19*
Pt06
0
12
24
36
48
Months

Figure 3


A
Pre-surgery 1
Post-surgery 1
Pre-surgery 2
B
CD3+
20 µm
Surgery 1
C
****
CD3+ cell/mm2
600
400
200
0
Surgery 1
Surgery 2
D
CD3+
20 µm
Surgery 2
E
CD8+
20 µm
Surgery 1
F
****
CD8+ cells/mm2
600
550
500
450
400
100
50
0
Surgery 1
Surgery 2
G
CD8+
20 µm
Surgery 2

Figure 4

A Primary Tumor

B Tumor Recurrence

Patient 1



C

	Primary Tumor	Tumor Recurrence
	Granzyme B+	Granzyme B+
	IBA1+/CD4+	IBA1+/CD4+/CD8+
	IBA1+/CD4+/CD107a+/CD8+	IBA1+/CD4+/CD8+
	IBA1+	IBA1+
	CD107a+	CD107a+
	IBA+/CD4+/CD107a+ cells	IBA1+ /CD4+/CD8+/CD107a+
	B+/CD4+/CD8+/CD107a+	Granzyme B+/CD107a+
	IBA+/CD107a+	CD107a+
	IBA1+/ CD4+/CD107a+	IBA1+/CD4+

D Primary Tumor

E Tumor Recurrence

Patient 7



F

	Primary Tumor	Tumor Recurrence
	Granzyme B+ /CD8+	Granzyme B+
	IBA1+	CD4+/CD8+
	IBA1+/CD4+/CD8+	IBA1+/CD4+/CD8+/CD107a+
	IBA1+	IBA1+
	CD107a+	CD107a+
	IBA1+/CD4+/CD107a+	IBA1+ /CD4+/CD8+/CD107a+
	B+/CD4+/CD8+/CD107a+	B+/IBA+/CD4+/CD8+
	CD107a+	CD107a+
	IBA1+/ CD4+/CD107a+	IBA1+/CD4+/CD107a

G

	IBA1	CD4	Granzyme B	CD107a	CD8
IBA1	0	-0.07	0.23	-0.38	0.52
CD4	-0.07	0	0.27	-0.37	0.55
Granzyme B	0.23	0.27	0	0.4	-0.49
CD107a	-0.38	-0.37	0.4	0	0.27
CD8	0.52	0.55	-0.49	0.27	0

H

	IBA1	CD4	Granzyme B	CD107a	CD8
IBA1	0.00	-0.04	0.11	-0.11	0.44
CD4	-0.04	0.00	0.11	-0.18	0.56
Granzyme B	0.11	0.11	0.00	0.08	-0.55
CD107a	-0.11	-0.18	0.08	0.00	0.36
CD8	0.44	0.56	-0.55	0.36	0.00

FIGURE LEGENDS

FIGURE 1: Overcoming lack of CNS dendritic cells by *in situ* immunotherapy using FLT3L and HSV1-TK

A) The central nervous system (CNS) lacks functional dendritic cells, thus resulting in failure to initiate effective immune response against high grade glioma (HGG). **B)** Using *in situ* immunotherapy with FLT3L at the tumor bed, a cytokine known to cause proliferation of dendritic cells, causes the migration of dendritic cells into the tumor microenvironment. By combining FLT3L and HSV1-TK, a cytotoxic vector, dendritic cells are recruited to choose tumor antigens within the glioma microenvironment and initiate systemic immunity, thus overcoming lack of CNS dendritic cells. **C)** In this study, adults with newly diagnosed HGG who underwent maximal safe resection received injection of HSV1-TK and Flt3L adenovectors to the tumor bed, followed by two 14-day cycles of valacyclovir and standard-of-care upfront chemoradiation.

FIGURE 2: Dual viral vector approach shows encouraging survival outcomes.

A) Using Kaplan-Meier method, median overall survival was 21.3 months. **B)** Swimmer plots of bars representing each study subject's overall survival in months, noting those with steroid use at the time of enrollment. One patient with rightward arrow is still alive and is currently followed for survival. Annotations correspond to respective timings of progression per iRANO criteria (if known), subsequent surgery with confirmatory histopathology for tumor progression or pseudoprogression, and radiographic changes associated with pseudoprogression. One patient had the diagnosis of anaplastic astrocytoma (**) and all other patients had the diagnosis of glioblastoma, including three with the gliosarcoma variant (*). All 18 subjects had the frozen pathology of malignant glioma prior to enrollment at the time of tumor resection.

23 **FIGURE 3: Immunohistochemical analysis of CD3+ and CD8+ cells in human glioblastoma tissue at**
24 **primary resection, pre-vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence.**
25 **A)** MRI of patient before primary resection (surgery 1) on date 4/7/14, Secondary surgery on date
26 7/16/14 and surgery 3 on 5/12/2021. **B and D**) Representative images of CD3 expression. Scale bar: 20
27 µm. **C)** Box plots and lines graphs represent the quantification of CD3+ cells numbers (cells/mm^2) using
28 QuPath positive cell detection on glioblastomas samples obtained pre-TK-Flt3 treatment (Surgery 1) and
29 post-surgery upon recurrence (Surgery 2). Error bars represent ±SEM. n=8 patients, **** $p<0.0001$. **E**
30 **and G**) Representative images of CD8 expression. Scale bar: 20 µm. **F)** Box plots and lines graphs
31 represent the quantification of CD8+ cells numbers (cells/mm^2) using QuPath positive cell detection on
32 glioblastomas samples obtained pre-TK-Flt3 treatment (Surgery 1) and post-surgery upon recurrence
33 (Surgery 2). Error bars represent ±SEM. n=8 patients, **** $p<0.0001$.
34 **FIGURE 4**. **CytoMAP analysis of the immune microenvironment in glioblastoma tissues at primary**
35 **tumor resection and at tumor recurrence.** 50 µm raster scanned neighborhoods were clustered into 11
36 regions. **(A)** Plot shows these regions in tissue obtained at primary tumor resection from patient 1. **(B)**
37 Plot shows tissue from tumor resection at recurrence from patient 1. **(C)** Markers occurring at greater
38 than average frequency within each region as compared to the whole tissue for patient 1, primary and
39 recurrent tumor. Note that, for **C** and **F**, based on the higher density of NeuN in dark blue areas (data
40 not shown), and their lower content of immune cells, these areas are most likely non-tumor areas
41 bordering the tumor areas proper. **(D)** Plot shows tissue obtained at resection of primary tumor from
42 patient 7. **(E)** Plot shows tissue resected at tumor recurrence from patient 7. **(F)** Markers occurring at
43 greater than average frequency within each region as compared to the whole tissue for patient 7, at
44 primary and recurrent resections. **(G)** Pearson correlation coefficient differences (blue boxes, >0,
45 indicate positive correlations; rose boxes, <0, indicate negative correlations) between primary tumor

46 resection and recurrence in patient 1. **(H)** Pearson correlation coefficient differences between primary
47 tumor and recurrence in patient 7. Please note that trends in correlations between different cell markers
48 are similar in both patients. For example, correlations between CD8+ cells and IBA1+ cells increase from
49 first surgery to recurrence in patient 1, as well as in patient 7 (see yellow boxes in G (patient 1) and H
50 (patient 7)). In both patients, CD4+ T cells display reduced CD107a and increased Granzyme B (see black
51 boxes in G (patient 1) and H (patient 7)). In contrast, in both patients, CD8+ T cells displayed increased
52 CD107a and reduced Granzyme B (see red boxes in G (patient 1) and H (patient 7)). The changes in
53 CD107a and Granzyme B most likely indicate a reduction in the functional activities of CD8+, and CD4+ T
54 cells. CD8+, and CD4+ T also increase their joint co-distribution (light blue box in G and H). The yellow
55 boxes in G and H indicate an increase in the co-localization of macrophages/microglia with CD8 T cells.
56 Possibly, this increased interaction could be responsible for the functional inhibition of T cells. Blue areas
57 were areas devoid of any immune cells.

SUPPLEMENTAL APPENDIX

TABLE OF CONTENTS

Supplementary Methods: Eligibility 2
Supplementary Methods: Schedule of Assessments 4
Supplementary Methods: Protocol Treatment Plan 5
Supplementary Methods: Toxicities and Dose Delays 7
Supplementary Methods: Toxicity Evaluation 9
Supplementary Methods: Clinical and Imaging Evaluation 9
Supplementary Methods: Correlative Studies 10
Supplementary Results: Study Treatment Tolerability 12
Supplementary Results: MRI Studies 12
Table S1. Dual Viral Vector Dosing 13
Table S2. Dose Modification for Valacyclovir 14
Table S3. Renal Adverse Event Management Algorithm for Valacyclovir 15
Table S4. All Serious Adverse Events 16
Table S5. Adverse Events Unrelated to Study Intervention 17
Table S6. Neutralizing anti-adenovirus antibody titer levels 18
Supplemental Figure S1 19
Supplemental Figure S2 20
Supplemental Figure S3 21
Supplemental Figure S4 22
Supplemental Figure S5 23
Supplemental Figure S6 24
Supplemental Figure S7 25
Supplementary References 26

Supplementary Methods: Eligibility

Inclusion Criteria

1. Newly identified supratentorial brain lesion compatible with a diagnosis of high-grade glioma (WHO III or IV) by MR with no prior treatment with either gene therapy, chemotherapy or radiation treatments that is amenable to attempted gross total resection (GTR). "High grade glioma" can include Glioblastoma multiforme (WHO grade IV); Gliosarcoma (WHO grade IV); Anaplastic astrocytoma (WHO grade III); Anaplastic oligodendroglioma (WHO grade III); and Anaplastic ependymoma (WHO grade III).
2. Intraoperative histological frozen section analysis at the time of tumor resection shown to be compatible with high-grade glioma or malignant glioma (as described elsewhere throughout this document). If intraoperative diagnosis was not compatible with high grade glioma, the patient was not enrolled.
3. Karnofsky Performance Status (KPS) score ≥70
4. Laboratory Values
5. CBC/differential obtained within 14 days prior, with adequate bone marrow function were defined as follows:
    1. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3;
       Platelets ≥ 100,000 cells/mm3;
       Hemoglobin ≥ 10.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥10.0 g/dl is acceptable.);
    2. Adequate renal function, as defined below:
       BUN ≤ 30 mg/dl within 14 days prior.
       Creatinine ≤ 1.7 mg/dl within 14 days prior.
    3. Adequate hepatic function, as defined below:
       Bilirubin ≤ 2.0 mg/dl within 14 days prior.
       ALT/AST ≤ 3x laboratory upper limit of normal within 14 days prior.
6. Male and female; both genders must use contraception if of reproductive capacity
7. For women of childbearing potential, a negative pregnancy test performed within 14 days of surgery
8. Capable of informed consent
9. 18-75 years of age

Exclusion Criteria

1. Diffusely multifocal lesion

2. Lesions not amenable to GTR
3. Tumors infiltrating the cerebellum, bilateral corpus callosum ("butterfly glioma"), ventricular system, or brain stem
4. Infratentorial high grade glioma
5. Primary central nervous system (CNS) disease that would interfere with subject evaluation
6. Prior history of other cancer within 5 years except curative cervical cancer in situ, basal or squamous cell carcinoma of the skin.
7. Evidence of other significant disease including hematologic, renal or liver disease that is not explained by the patient's current medical condition or concomitant disease.
8. Patient known to have HIV, Hepatitis B, Hepatitis C.
9. Active systemic infection
10. Immunosuppressive disorders (i.e., chronic steroid therapy, acquired or congenital immune deficiency syndromes, autoimmune disease)
11. Serious medical conditions (i.e., CHF, angina, diabetes mellitus Type 1, COPD, bleeding diathesis)
12. Any contraindication for undergoing MRI
13. Pregnant or lactating females
14. Unacceptable anesthesia risk
15. Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery.
16. Prior gene therapy
17. Allergy to valacyclovir
18. Unable to take oral tablets

Supplementary Methods: Schedule of Assessments

	Screening (<14 days prior to surgery)	Day 0 (prior to surgery)	Day 0 (during surgery)	Day 2 ± 1 day	Week 2 ± 1 wk Neurosurgery visit	Week 1-3 NeuroOnc visit	Week 6 ± 2 wk	Week 10 ± 2 wk	Week 14 ± 2 wk	Week 18 ± 2 wk	12-Months Follow up[8]	24-Months Follow up[8]	Overall Survival[8]
Medical History	x				x	x	x	x	x	x			
Physical Exam	x				x	x	x	x	x	x			
Karnofsky Performance Status	x				x	x	x	x	x	x			
Vital Signs[1]	x	x				x							
Hematology[2]	x			x	x								
Clinical Chemistry[3]	x			x	x								
MRI	x			x[5]			x	x	x	x			
ECG	x												
Pregnancy test (if applicable)	x	x				x	x	x	x	x			
Anti-Ad Abs	x				x		x	x					
Serum sample (stored)					x		x	x					
Blood sample (PMBC)	x				x		x	x					
Neurological Assessments[7]	x	x		x	x	x	x	x	x	x			
Histological confirmation of high-grade glioma			x[4]										
Vector delivery			x										
Start Valacyclovir[6]				x Round 1				x Round 2					
Concomitant medications		x		x	x	x	x[8]	x	x[8]	x			
Adverse events				x	x	x	x[8]	x	x[8]	x			
Survival follow up											x	x	x

1. Vital signs to include body weight, temperature, blood pressure, heart rate, respiration rate
2. Hematology panel to include CBC, WBC, Differential, PT/PTT (PT/PTT only at screening).
3. Clinical Chemistry to include glucose, calcium, albumin, total protein, electrolytes [sodium, potassium CO2, chloride], BUN, creatinine, alkaline phosphatase, ALT/SGPT, AST/SGOT, bilirubin.
4. Confirmation of malignant glioma leads to formal patient enrollment, and triggers preparation of viral vectors for treatment administration. At this time, surgery informs O-CTSU that biopsy confirms histological eligibility, and treatment proceeds.
5. Post-op MRI to determine the degree of tumor resection was obtained within the first 48 hours postoperatively
6. Valacyclovir was administered orally at 2g, 3 times daily for 14 days beginning 1-3 days after vector injection per clinician judgement. Round 2 entailed 14 days of treatment, 2g 3x/day.
7. Neurological Assessments include Mini Mental Status.
8. Survival follow-up information could be assessed by telephone calls, patient medical records, and/or clinic visits. If the patient withdrew from study, the study staff would have used a public information source (e.g., county records) when permissible, to obtain information about survival status only.

Supplementary Methods: Protocol Treatment Plan

Administration of Ad-hCMV-TK and Ad-hCMV-Flt3L

The total volume of Ad-hCMV-TK and Ad-hCMV-Flt3L injected was 2 ml.

Surgical Procedure

A craniotomy with resection of the tumor was performed. At the neurosurgeon's discretion, this involved stereotactic methods and/or intraoperative navigational guidance and/or intraoperative MRI or other radiologic guidance. After tumor resection had been completed and adequate hemostasis obtained, two tuberculin syringes were used to deliver the Ad-hCMV-TK and Ad-hCMV- Flt3L vector in 100 microliters at each to twenty sites. The assignment of dosages were determined preoperatively as per protocol (Table S1). Injections were done over 3-5 minutes for each syringe and each vector was delivered at random sites throughout the cavity. The vectors were brought from Research Pharmacy in sterile syringes as prepared under the supervision of a Research Pharmacist. Syringes containing vectors were delivered on ice to the OR. The surgeon placed a sterile 25-gauge needle on the syringe within the OR. The syringes did not remain in the OR for more than 4 hours before use. The injection sites were selected by the surgeon to avoid injections into adjacent motor or speech cortex, the cerebral ventricle, or seepage into the subarachnoid space. A total of 2ml of vectors will be injected as 0.1 ml/injection site across 20 sites. No injections were made into mapping-defined areas of eloquent brain to avoid any risk of injection-related complications in these areas. In addition, surgeons maintained a safety margin, such that injections of vectors were made at least one gyrus away from regions of eloquent brain. After the injections were complete, the needle was slowly withdrawn, and the remainder of the operation consisted of routine wound closure. The delivery of the viral vectors required an additional 10 minutes to the time of surgery.

Valacyclovir Administration

Valacyclovir treatment began 1-3 days after vector administration, at a dose of 2 grams given orally three times per day for a course of 14 days. A second course of valacyclovir was given beginning Week 10 (+/1-2 weeks). Valacyclovir was dispensed from the University of Michigan Research Pharmacy with a medication diary, which was turned in by the patient to the study team at the end of each course of Valacyclovir.

The capacity of Ad-hCMV-TK to kill glioma cells depends on three factors that need to be present simultaneously:

• the glioma cells need to express HSV1-TK;

• the nucleoside analogue valacyclovir needs to be present; and
• the cell must enter cell division (mitosis).

The second cycle of valacyclovir is designed to target and kill residual tumor cells infected with Ad-hCMV-TK that were not dividing during the first cycle. As the population of cells that are expressing TK that do not divide early is likely to be significant (based on patterns of glioma recurrence), the second cycle of valacyclovir may be able to kill these cells, and thus increase the potential to present antigens and toll receptor ligands to immune cells recruited to the tumor microenvironment by Ad-hCMV-Flt3L. The dose/schedule of Ad-hCMV-TK has been used in clinical trials for prostate, ovarian, and malignant glioblastoma. The dose of Ad-hCMV-Flt3L was determined in this clinical trial.

Radiation Therapy (standard of care)

RT was determined and administered as per standard-of-care for the individual patient by the treating Radiation Oncologist. For most patients, RT began 15-35 days after Ad-hCMV-TK and Ad-hCMVFlt3L injection. It consisted of standard external field radiation, limited to the area of the tumor and brain adjacent to the tumor. The most common regimen was 60 Gy, delivered as 2 Gy per day, 5 days/week for 6 weeks. Another standard regimen was 40.05 Gy, delivered as 2.67 Gy per day, 5 days/week for 3 weeks. Neither the performance of radiation, the timing, nor the details was directed by this protocol.

Temozolomide Therapy (standard of care)

Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Treatment with temozolomide was determined as per standard-of-care for the individual patient by the treating neuro-oncologist. It was anticipated that, for most patients, concomitant temozolomide would be taken with RT starting 15-35 days after Ad-hCMV-TK and Ad-hCMVFlt3L injection. It was also anticipated that, for most patients, the duration of concomitant temozolomide would coincide with the duration of RT, as described above. It was also anticipated that neither the performance of radiation, the timing, nor the details were directed by this protocol.

Pneumocystis carinii (PCP, also known as pneumocystic jirovecii) Prophylaxis

Some physicians recommend trimethoprim/sulfamethoxazole or other medications as prophylaxis for PCP for patients treated with temozolomide. There is no national standard-of care and no standard practice at the University of Michigan. The use of PCP prophylaxis was not directed by this protocol.

Maintenance Phase (Standard of Care)

Standard-of-care treatment generally includes cyclic temozolomide, starting about 4 weeks after completion of RT with concomitant temozolomide, take on 5 successive days every 28 days (1 cycle) for 6-12 cycles, if the tumor has not progressed. It was anticipated that most patients in this protocol would take 1-2 cycles of temozolomide during the 16-week period of intense monitoring. Decisions about cyclic temozolomide were made by the treating neuro-oncologist per standard of care. Neither the administration of cyclic temozolomide, its timing, nor its details are directed by this protocol.

Supplementary Methods: Toxicities and Dose Delays

Dose -Delays/ Potential Complications Specific to Adenoviral Vector Infusion

Fever may occur due to the local inflammatory and immune response to Ad-hCMV-TK and AdhCMV-Flt3L; acetaminophen will be used as necessary. If grade 2 or greater NCI CTCAE v.4 criteria for infection of the surgical wound is present (i.e., requiring systemic antibiotics therapy for treatment), valacyclovir was not started or stopped. If the course of valacyclovir had not yet been started, then the patient would receive the full dose. If the course of valacyclovir had been stopped, then the patient would receive the remainder. Any such dose modification was noted.

In previous clinical trials evaluating Ad-hCMV-TK followed by prodrug administration, toxicity had been rare and the overall approach had been well tolerated. In a similar study in recurrent brain tumors, CNS toxicity (lethargy, confusion, grade 3 hyponatremia, fever, leukocytosis, intratumoral hemorrhage, and hydrocephalus) was observed in the $2x10^{12}$ vp dose level. In the lower dose levels, no DLTs were observed; however transient and less severe events included seizure, small intratumoral hemorrhage, worsening of neurologic symptoms, mild hyponatremia. However, as the combination of Ad-hCMV-TK and Ad-hCMV-Flt3L in combination with surgery, radiation therapy, and chemotherapy had not yet been evaluated in human clinical trials, we chose to evaluate in the Phase 1 study dose levels of Ad-hCMV-TK that had been shown to be well tolerated over a number of studies.

Valacyclovir

The most common adverse events with valacyclovir reported in the prescribing literature are nausea in 6-15% of patients, headache in 14-35%, vomiting in 1-6%, dizziness or abdominal pain in 2-11%, arthralgia in 1-6% and depression in 1-7%. Laboratory abnormalities such as abnormal liver function tests had been observed in 1-4% of patients, while anemia, leucopenia, thrombocytopenia and elevated serum creatinine occurred in 1% of patients or less. In addition, the following adverse events have been identified in clinical practice: allergic reactions (anaphylaxis, angioedema, dyspnea, pruritus, rash and uticaria), CNS symptoms

(confusion, insomnia, hallucinations, agitation, aggressive behavior, mania), gastrointestinal (diarrhea), renal failure, erythema multiforme, facial edema, hypertension and tachycardia. A rare but serious adverse event of thrombotic thrombocytopenia purpura/hemolytic uremic syndrome (TTP/HUS), in some cases resulting in death, has been observed in clinical trials of high dose valacyclovir (8 grams per day) in patients with advanced HIV infection, and in allogeneic bone marrow transplant and renal transplant recipients.

Valacyclovir Dose Modifications (Dose Hold, Delay or Discontinuation) due to AEs

Subjects who experience a Grade 3 or greater NCI CTCAE v.4 Thrombotic thrombocytopenia purpura or Grade 2 or greater Hemolytic uremic syndrome or Grade 3 or greater serum creatinine were managed as outlined below in Tables S2 and S3. Adjustments to the dose reduction guidelines was based on the clinical judgment of the Investigator with approval by the Medical Monitor.

- For all patients starting valacyclovir, baseline creatinine within 3 d before start of treatment, were measured.
- For patients who started with a normal/baseline creatinine level, recheck at day 7 + 2 d, was performed.
- For patients who started with elevated creatinine levels, recheck at least twice a week (every 4 d) through the 14 days, was performed

If dosing was delayed for 4 weeks or longer, the cycle of valacyclovir was discontinued.

For patients starting cycle 2 of valacyclovir who had creatinine elevation during cycle 1, the following criteria were used:

- If max creatinine was Grade 1, start at dose level 0 or lower at discretion of investigator; if started lower and tolerated, increase 1 level at discretion of investigator.
- If max creatinine was Grade 2, start at dose level -1 or lower at discretion of investigator; if tolerated, increase 1 level at discretion of investigator.

Temozolomide

Temozolomide is a standard-of-care treatment for glioblastoma. Its use was not mandated or directed by the protocol, but it was expected that most patients would receive it. In patients receiving temozolomide, toxicities known compatible with temozolomide as the cause will not be considered as DLTs from the treatments administered as part of this study.

Patients treated with temozolomide have reportedly experienced myelosuppression including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome. In some cases, exposure to concomitant medications associated with aplastic anemia including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim complicates assessment. Geriatric patients and women have been shown in clinical trials to have a higher risk of developing myelosuppression.

Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have also been observed. Prophylaxis against Pneumocystis carinii pneumonia will be left to the discretion of the treating physician. There may be a higher occurrence of PCP when temozolomide is administered during a longer dosing regimen. However, all patients receiving temozolomide, particularly patients receiving steroids, should be observed closely for the development of PCP regardless of the regimen.

Grade 3/4 neutropenia occurred in 8% and Grade 3/4 thrombocytopenia in 14% of patients treated with temozolomide. The most common side effects associated with temozolomide therapy are nausea, vomiting, anorexia, alopecia, headache, fatigue, constipation, convulsions, weakness, and thrombocytopenia.

Supplementary Methods: TOXICITY EVALUATION

Toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version v4.0. Any one of the following occurring within 21 days of dual vector administration was considered a dose-limiting toxicity (DLT): 1) Grade 4 toxicity for constitutional symptoms with the exception of fever > 40°C for ≤ 24 hours, 2) ≥ Grade 3 neurologic toxicity relative to the changes from the pre-treatment neurological status and attributable to the study therapy regimen, 3) ≥ Grade 3 or greater non-hematologic toxicity attributable to the study therapy regimen, and 4) ≥ Grade 2 or greater autoimmune events.[1-3]

Supplementary Methods: CLINICAL AND IMAGING EVALUATION

Subjects were followed closely with clinical and radiographical assessments for 30 days after the completion of the second valacyclovir course, approximately 16 weeks from the dual vector administration, and thereafter for survival. Disease progression was determined using the immunotherapy response assessment in neuro-oncology (iRANO) criteria.[4] Detailed Schedule of Assessments can be found in the Supplemental Methods Section in the Supplementary Appendix.

The relationship between pre-operative diffusion-weighted imaging (DWI) and dynamic susceptibility contrast (DSC) perfusion-weighted imaging parameters and survival were analyzed using Pearson's correlation analyses. The mean apparent diffusion coefficient (ADCmean), relative cerebral blood flow

(rCBF), and relative cerebral volume (rCBV) were measured using volume-of-interest placed on the enhanced areas of the tumors. Normalized ADCmean (nADCmean), normalized rCBF (nrCBF), and normalized rCBV (nrCBV) were calculated by dividing by the reference values which were measured using three separate region-of-interests placed in the normal-appearing white matter.

Supplementary Methods: CORRELATIVE STUDIES

Immunohistochemistry on paraffin embedded brain biopsies (IHC-DAB)

The resected tumor tissues from the primary resections on study, as well as available tumor tissue from the second resection, were analyzed by immunohistochemistry, and by multiplex immunohistochemistry.[5-8] Brain sections were subjected to endogenous peroxidase quenching, carried out using a 0.3% H_2O_2 incubation for 5 minutes at room temperature, followed by heat-induced antigen retrieval, performed using 10 mM citric acid, 0.05% Tween 20, pH 6.0. Tissue permeabilization and blocking were completed using PBS 0.2% Tween-20 with 5% goat serum for one hour at room temperature. Tissue was then incubated with primary antibodies at 4°C overnight with concentrations as indicated: **CD45 (Cell signaling #13917, 1:1000), CD3e (Cell signaling #85061, 1:400), CD11c (Cell signaling #45581, 1:1000), CD68 (Abcam ab955, 1:200), CD19 (Cell signaling #90176, 1:400), CD8 (Leica NCLL-CD8-4B11, 1:100), CD4 (Cell signaling # 48274, 1:500).** Sections were then incubated with biotinylated secondary antibodies at a 1:1000 dilution in PBS with 0.2% Tween-20 overnight at 4°C (Polyclonal Goat Anti-Rabbit Immunoglobulins/Biotinylated, Dako E0464, or Polyclonal Goat Anti-Mouse Immunoglobulins/Biotinylated, Dako E0433). ABC Avidin-Biotin-Complex Binding reagent (Vectastain Elite ABC kit) and Betazoid DAB Chromogen detection kit (BioCare BDB2004) were used according to the manufacturer's instructions. The IHC-stained slides were then digitized at a single focal plane level at ×40 magnification. Positive cells in the whole sections were quantified using QuPath v 0.3.0.

Statistical analysis of immunohistochemistry

For each marker (i.e., CD8), a linear mixed effects (LME) model was used to compare NumPos (log-transformed) between two surgery procedures. Random effect was included in the LME model to consider correlations between data measured on the same subject. Significance is determined if $p<0.05$. All analyses were conducted using SAS (version 9.4, SAS Institute, Cary, NC).

Multiplex immunofluorescence and analysis using the Akoya phenocycler-fusion.

Multiplex immunofluorescence of all FFPE tissue (Figure 4) was performed on a PhenoCycler-Fusion by Akoya Biosciences per manufacturer's instructions with the following addition. After antigen retrieval, a photobleaching protocol was performed in order to reduce autofluorescence. Briefly, slides were submerged

in a solution of 30% w/v hydrogen peroxide, 1x PBS and 1M sodium hydroxide and sandwiched between two full spectrum LED light boxes for thirty minutes. Samples were then equilibrated in four three-minute 1x PBS washes before continuing with the remainder of the Akoya protocol. The following Akoya antibodies with associated reporters were used for staining: Anti-Hu CD8 (AKYP0028)-BX026—Atto 550, Anti-Hu CD4 (AKYP0048)-BX003—Alexa Fluor™ 647, Anti-Hu Granzyme B (AKYP0086)-BX041—Atto 550, and Anti-Hu CD107a(AKYP0004)-BX006—Alexa Fluor™ 647, all for PhenoCycler. The Anti-Hu IBA1 antibody was custom conjugated to a barcode by Akoya using IBA1 antibodies from Abcam (catalog number Ab221790) and was visualized using an Alexa Fluor™ 488 reporter. For the Akoya protocol, samples are stained with antibodies conjugated to unique oligonucleotide sequences (i.e. barcodes). Reporters, consisting of fluorophores attached to oligonucleotide sequences complementary to those on the barcodes, are hybridized and imaged three at a time in consecutive cycles on the Phenocycler-Fusion platform.

After the PhenoCycler-Fusion run was complete, the QPTIFF images were imported into QuPath for cell segmentation and phenotyping using artificial neural network training. After classification of all cells was complete, data was exported into CytoMAP for neighborhood analysis. Raster scanned neighborhoods with a 50-micron radius were defined. Resulting neighborhoods were then clustered into regions using Davies Bouldin criteria and the NN self-organizing map algorithm. Pearson correlation coefficients for each marker in each sample were then calculated in CytoMAP.

Antibody measurements

Prior to viral vector injection, circulating neutralizing anti-adenovirus antibody titers were measured,[9-11] then at week 1, 2, 6, 10 and 48. The titers were expressed as follows: 1:16, is expressed as 16, etc.; the higher the number the higher the anti-adenoviral titer. The neutralizing anti-adenovirus antibody titers were measured in patients' serum samples. Sera were heat-inactivated at 56 °C for 30 min and serially diluted 2-fold in DMEM with 10% FBS 12 times (1:2- 1:4096). Each dilution was incubated with $1x10^6$ i.u. of RAd35 (Ad-hCMV-LacZ) for 90 min at 37 °C. Volumes of 50 µL of each dilution were transferred to 96-well plate containing 4 x 10^4 HEK 293 cells for 60 min at 37 °C (performed by triplicates), followed by a 50 µL addition of DMEM with 10% FBS in each well. After 20h at 37 °C cells were fixed with 4% paraformaldehyde in PBS and stained with 5-bromo-4chloro-indolyl-ß-D-galactoside (X-gal). The neutralizing anti-adenovirus antibody titers for each sample was defined as the reciprocal of the highest dilution of serum at which 50% of RAd35-mediated transduction was inhibited.

Supplementary Results: STUDY TREATMENT TOLERABILITY

Six subjects (33%) experienced adverse events that were at least possibly related to study treatment which ranged from CTCAE grades 1 to 3 (Table 1B) and consisted of one subject per following toxicities: dyspepsia (grade 1), elevated creatinine (grade 2), dizziness (grade 1), encephalopathy (grade 3), headache (grade 1), seizure (grade 2 & 3), confusion (grade 2), hallucinations (grade 1), acute kidney injury (grade 3), and maculo-papular rash (grade 1).

Ten subjects experienced serious adverse events (Supplemental Appendix Table S4) which ranged from CTCAE grades 2 to 5. Serious adverse events in all but one subject were deemed unrelated to the study treatment. One subject experienced three serious adverse events of grades 2-3, which were possibly related to study treatment. Serious adverse events possibly related to the study treatments were grade 2 seizure (n=1), grade 3 encephalopathy (n=1), and grade 3 acute kidney injury (n=1) in the same patient, which were possibly related to valacyclovir. No dose-limiting toxicity of the dual viral vectors was observed, and the maximal tolerated dose of HSV-TK and Flt3L vectors was not reached. Other adverse events which were unrelated to study treatments are summarized in the Table S5 in the Supplemental Appendix; (see also Supplementary Methods: Toxicities and Dose Delays).

Supplementary Results: MRI Studies

An association between lower ADC (apparent diffusion coefficient) values and poor survival have been reported in glioblastoma.[12-14] A systematic review and meta-analysis data also suggest significant correlation of pretreatment low ADC values with poor survival in patients with recurrent GBM treated with bevacizumab.[14] Given the heterogeneity of the treatment course among the patients in this study such as additional resection that modify the appearance of target lesion at the follow up imaging, the pre-operative baseline DWI and DSC parameters were analyzed. Although no significant correlations were found between MRI parameters and survival, there were weak correlations between baseline pre-operative nrCBV and OS, and between pre-operative nADCmean and OS.

Table S1. Dual Viral Vector Dosing

Cohort	Ad-hCMV-TK (10^N vp)	Ad-hCMV-Flt3L (10^N vp)
A	10	9
B	11	9
C	10	10
D	11	10
E	10	11
F	11	11

Table S2. Dose Modification for Valacyclovir

Dose level	
0 (starting)	2 g TID
-1	2 g BID or 1 g TID
-2	1 g BID or 0.5 g TID

Table S3. Renal Adverse Event Management Algorithm for Valacyclovir

Grade of Creatinine Elevation (NCI CTCAE v4.0)	Management	Follow up
Grade 0 (i.e. normal / baseline)	Check creatinine at day 7 ± 2 days	If creatinine recheck is abnormal, continue to recheck at least twice a week through the 14 day course of valacyclovir.
Grade 1 Creatinine >1 to 1.5 x baseline; >ULN to 1.5 x ULN	Dose level level -1	If creatinine remains Grade 1 or returns to Grade 0, continue level -1. If creatinine reaches to Grade 2, reduce to level -2. If creatinine reaches Grade 3-4 withhold valacyclovir.
Grade 2 Creatinine >1.5 to 3 x baseline; >1.5 to 3 x ULN	Dose level level -2	If creatinine returns to baseline, continue dose level -1. If creatinine reaches to Grade 2, reduce to level -2. If creatinine reaches Grade 3-4, withhold valacyclovir.
Grade 3 Creatinine > 3 x baseline; >3 to 6 x ULN	Withhold valacyclovir	If creatinine returns to Grade 0, restart at level -1. If creatinine returns to Grade 1, restart at level -2. If creatinine reaches Grade 3 a second time during cycle of valacyclovir, permanently discontinue unless an associated cause was present (dehydration, concomitant medication) and can be avoided. In such a situation, restart at level -2 and increase to level -1 at discretion of investigator.
Grade 4 Creatinine >6 x ULN	Withhold valacyclovir	If creatinine returns to Grade 0, restart at level -1. If creatinine returns to Grade 1, restart at level -2.

Table S4. All Serious Adverse Events

Event	Any Grade *no. (%)*	Grade 2-3 *no. (%)*	Grade 4-5 *no. (%)*
Gastrointestinal disorders			
Nausea	1 (6)	1 (6)	-
General disorders and administration site conditions			
Pain	2 (11)	2 (11)	-
Infections and infestations			
Urinary tract infection	2 (11)	2 (11)	-
Wound infection	4 (22)	4 (22)	-
Injury, poisoning and procedural complications			
Wound dehiscence	1 (6)	1 (6)	-
Metabolism and nutrition disorders			
Dehydration	1 (6)	1 (6)	-
Nervous system disorders			
Cognitive disturbance	1 (6)	1 (6)	-
Dysphasia	2 (11)	2 (11)	-
Edema cerebral	1 (6)	-	1 (6)
Encephalopathy	1 (6)	1 (6)*	-
Intracranial hemorrhage	1 (6)	-	1 (6)
Lethargy	1 (6)	1 (6)	-
Right side neglect	1 (6)	1 (6)	-
Seizure	2 (11)	2 (11)*	-
Syncope	1 (6)	1 (6)	-
Confusion	1 (6)	1 (6)	-
Renal and urinary disorders			
Acute kidney injury	1 (6)	1 (6)*	-
Respiratory, thoracic and mediastinal disorders			
Respiratory failure	1 (6)	-	1 (6)
Vascular disorders			
Thromboembolic event	5 (28)	5 (28)	-
Total no. patients with SAE	10 (56)	9 (50)	3 (17)

*Possibly attributable to study intervention

Table S5. Adverse Events Unrelated to Study Intervention

Event	Grade 2-3 *no. (%)*	Grade 4-5 *no. (%)*
Blood and lymphatic system disorders		
Anemia	4 (22)	-
Cardiac disorders		
Pericardial effusion	1 (6)	-
Ear and labyrinth disorders		
Vestibular disorder	1 (6)	-
Gastrointestinal disorders		
Abdominal pain	3 (17)	-
Diarrhea	1 (6)	-
Dysphagia	1 (6)	-
Nausea	3 (17)	-
General disorders and administration site conditions		
Edema limbs	2 (11)	-
Fatigue	8 (44)	-
Pain	3 (17)	-
Infections and infestations		
Upper respiratory infection	2 (11)	-
Urinary tract infection	3 (17)	-
Wound infection	4 (22)	-
Injury, poisoning and procedural complications		
Wound dehiscence	1 (6)	-
Investigations		
Creatinine increased	2 (11)	-
Neutrophil count decreased	1 (6)	-
Platelet count decreased	4 (22)	-
Metabolism and nutrition disorders		
Dehydration	2 (11)	-
Hyperkalemia	1 (6)	-
Hypokalemia	1 (6)	-
Musculoskeletal and connective tissue disorders		
Arthralgia	1 (6)	-
Generalized muscle weakness	2 (11)	-
Muscle weakness lower limb	1 (6)	-
Muscle weakness right-sided	1 (6)	-
Pain in extremity	1 (6)	-

Event (cont.)	Grade 2-3 *no. (%)*	Grade 4-5 *no. (%)*
Nervous system disorders		
Cognitive disturbance	1 (6)	-
Dysarthria	2 (11)	-
Dysphasia	3 (17)	-
Edema cerebral	-	3 (17)
Facial muscle weakness	1 (6)	-
Headache	2 (11)	-
Intracranial hemorrhage	-	1 (6)
Lethargy	1 (6)	-
Paresthesia	1 (6)	-
Right side neglect	1 (6)	-
Seizure	2 (11)	-
Syncope	1 (6)	-
Visual field deficit	1 (6)	-
Psychiatric disorders		
Agitation	1 (6)	-
Confusion	1 (6)	-
Insomnia	1 (6)	-
Respiratory, thoracic and mediastinal disorders		
Hypoxia	1 (6)	-
Respiratory failure	-	1 (6)
Skin and subcutaneous disorders		
Alopecia	2 (11)	-
Thromboembolic event	7 (39)	-

Table S6. Neutralizing anti-adenovirus antibody titer levels

Cohort	Subject	Week 1	Week 2	Week 6	Week 10	Week 48
A	1					
	2					
	3					
B	5	64	>4096	ND	ND	>4096
	6	ND	1024	ND	ND	ND
	7	2048	>4096	ND	ND	ND
C	8	32	64	ND	ND	ND
	10	32	64	ND	ND	ND
	11	2	16	ND	ND	ND
D	12	8	>4096	>4096	ND	ND
	13	512	>4096	>4096	ND	>4096
	14	<2	512	1024	ND	ND
E	15	ND	>4096	ND	ND	ND
	16	<2	16	<2	ND	ND
	18	<2	>4096	ND	ND	ND
F	19	512	256	128	ND	ND
	20	<2	128	8	16	ND
	21	>4096	2048	512	ND	ND

ND = not determined

Supplemental Figure S1





C

Expected (EcoRV)	Actual (EcoRV)	Expected (HindIII)	Actual (HindIII)
7637	7637	8009	8009
6965	6935	5553	5553
6355	6355	5322	5322
4545	4545	4597	4597
2617	2617	2937	2937
2182	2182	2927	2927
2052	2052	2081	2081
1238	1238	1824	1824
1106	1106	1008	1008
104		468	
		75	

Supplemental Figure S1. Ad-hCMV-TK expresses bioactive transgene Herpes Simplex Type 1 Thymidine kinase (TK). A) CNS1 rat glioma cells (2 x 104/well) were infected with Ad-hCMV-TK with either 10,000, 1,000, 100, 10, 0 Ad-hCMV-TK/cell. After 24 hours, the cells were incubated for additional 72 hours in the presence of 1 mg/mL of the prodrug ganciclovir (GCV). Cell viability was determined by CTG assay (Cell Titer-Glo Cell Viability Assays, Promega, Madison, WI). **B)** Restriction Analysis of Ad-hCMV-TK. Viral DNA was isolated from Ad-hCMV-TK, digested with either HindIII or EcoRV, and run on a 0.8% agarose gel. Image of gel electrophoresis displays a gel after 90 min of electrophoresis. **C)** Table comparing the predicted and actual DNA size following restriction analysis. All sizes are described in base pairs (bp).

Supplemental Figure S2



C

Expected (EcoRV)	Actual (EcoRV)	Expected (HindIII)	Actual (HindIII)
8139	8139	8009	8009
7637	7637	5553	5553
6355	6355	5322	5322
4545	4545	4597	4597
2617	2617	2997	2997
2182	2182	2927	2927
2052	2052	2081	2081
1238	1238	1432	1432
		1008	
		468	
		410	
		75	

Supplemental Figure S2. Ad-hCMV-Flt3L expresses its transgene Human soluble fms-like tyrosine kinase 3 ligand. A) CNS1 rat glioma cells (2 x 104/well) were infected with Ad-hCMV-Fl3tL with either 10,000, 1,000, 100, 10, 0 Ad-hCMV-Fl3tL /cell. After 72 hours, the levels of hFlt3L were measured in the cell supernatants using Flt3L specific ELISA. **B)** Restriction Analysis of Ad-hCMV-TK. Viral DNA was isolated from Ad-hCMV-Flt3L, digested with either HindIII or EcoRV, and run on a 0.8% agarose gel. Image of gel electrophoresis displays a gel after 90 min of electrophoresis. **C)** Table comparing the predicted and actual DNA size following restriction analysis. All sizes are described in base pairs (bp).

Supplemental Figure S3



Supplemental Figure S3. The consort flow diagram. Flow diagram of the enrollment, intervention allocation, follow-up, and data analysis of the dose-finding trial of combined cytotoxic and immune-stimulatory and adenovirally mediated strategy using FLT3L and HSV1-TK.

Supplementary Figure S4



Supplemental Figure S4. Immunohistochemical analysis of CD45+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence. A and C) Representative images of CD45 expression. Scale bar: 20 µm. **B)** Box plots and lines graphs represent the quantification of CD45+ cells numbers (cells/mm2) using QuPath positive cell detection on glioblastomas samples obtained pre-TK-Flt3 treatment (Surgery 1) and post-TK-FLt3 treatment (Surgery 2). Error bars represent ±SEM. n=8 patients, ns = non-significant.

Supplementary Figure S5



Supplemental Figure S5. Immunohistochemical analysis of CD68+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence. A and C) Representative images of CD68 expression. Scale bar: 20 µm. **B)** Box plots and lines graphs represent the quantification of CD68+ cells numbers (cells/mm2) using QuPath positive cell detection on glioblastomas samples obtained pre-TK-Flt3 treatment (Surgery 1) and post-TK-FLt3 treatment (Surgery 2). Error bars represent ±SEM. n=8 patients, ns = non-significant.

Supplementary Figure S6



Supplemental Figure S6. Immunohistochemical analysis of CD4+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence. A and C) Representative images of CD4 expression. Scale bar: 20 µm. **B)** Box plots and lines graphs represent the quantification of CD4+ cells numbers (cells/mm2) using QuPath positive cell detection on glioblastomas samples obtained pre-TK-Flt3 treatment (Surgery 1) and post-TK-FLt3 treatment (Surgery 2). Error bars represent ±SEM. n=8 patients, ns = non-significant.

Supplementary Figure S7



Supplemental Figure S7. Immunohistochemical analysis of CD11c+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence. A and C) Representative images of CD11c expression. Scale bar: 20 µm. **B)** Box plots and lines graphs represent the quantification of CD11c+ cells numbers (cells/mm2) using QuPath positive cell detection on glioblastomas samples obtained pre-TK-Flt3 treatment (Surgery 1) and post-TK-FLt3 treatment (Surgery 2). Error bars represent ±SEM. n=8 patients, ns = non-significant.

Supplementary References:

1. Wheeler LA, Manzanera AG, Bell SD, et al. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro Oncol 2016;18(8):1137-45. DOI: 10.1093/neuonc/now002.
2. Chiocca EA, Aguilar LK, Bell SD, et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol 2011;29(27):3611-9. DOI: 10.1200/JCO.2011.35.5222.
3. Desjardins A, Gromeier M, Herndon JE, 2nd, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med 2018;379(2):150-161. DOI: 10.1056/NEJMoa1716435.
4. Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 2015;16(15):e534-e542. DOI: 10.1016/S1470-2045(15)00088-1.
5. Ali S, King GD, Curtin JF, et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer research 2005;65(16):7194-204. (In eng). DOI: 10.1158/0008-5472.Can-04-3434.
6. Nunez FJ, Mendez FM, Garcia-Fabiani MB, et al. Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures. J Vis Exp 2019(143). DOI: 10.3791/58931.
7. Nunez FJ, Mendez FM, Kadiyala P, et al. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med 2019;11(479). DOI: 10.1126/scitranslmed.aaq1427.
8. Comba A, Faisal SM, Dunn PJ, et al. Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression. Nat Commun 2022;13(1):3606. DOI: 10.1038/s41467-022-31340-1.
9. Muhammad AK, Xiong W, Puntel M, et al. Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. Human gene therapy methods 2012;23(4):271-84. (In eng). DOI: 10.1089/hgtb.2012.060.
10. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A 2000;97(13):7482-7. DOI: 10.1073/pnas.120474397.
11. Puntel M, Kroeger KM, Sanderson NS, Thomas CE, Castro MG, Lowenstein PR. Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci 2010;Chapter 4:Unit 4 24. DOI: 10.1002/0471142301.ns0424s50.
12. Pope WB, Qiao XJ, Kim HJ, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 2012;108(3):491-8. DOI: 10.1007/s11060-012-0847-y.
13. Schell M, Pfluger I, Brugnara G, et al. Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro Oncol 2020;22(11):1667-1676. DOI: 10.1093/neuonc/noaa120.
14. Kurokawa R, Baba A, Kurokawa M, et al. Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A

Systematic Review and Meta-analysis. AJNR Am J Neuroradiol 2022;43(2):202-206. DOI: 10.3174/ajnr.A7406.